I-MED Pharma Wins Patent Case Against TearLab

World News: . []

MONTREAL, Feb. 13, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., announced today that TearLab’s efforts to keep the I-PEN Osmolarity System off the market proved unsuccessful. I-MED Pharma wins patent case against TearLab, with costs awarded to I-MED.

In February 2016, TearLab brought a suit in the Federal Court of Canada alleging that the I-PEN sold in Canada by I-MED Pharma infringed Canadian Patent No. 2,494,540. TearLab sells the TearLab Osmolarity System in Canada. TearLab sought a permanent injunction to keep the I-PEN off the market as well as damages. 

On February 12, 2018, the Court found in I-MED Pharma’s favour. I-MED successfully invalidated each and every claim of the Patent that TearLab relied upon to block the sale of the I-PEN in Canada. The Court awarded costs in favour of I-MED Pharma.  

“This is a very important win for us” said Daniel Hofmann, CEO of I-MED. “Our patented I-PEN device responds to a market need for an affordable, reliable, efficient hand-held device for use by eye-care professionals when diagnosing and monitoring dry eye disease. We invested significant time and resources in order to deliver an innovative and game changing product to our customers. Our market share is growing as more eye-care professionals realize the benefits of the I-PEN. Rather than compete fairly with us in the marketplace, TearLab commenced a lawsuit seeking to keep us off the market. Today’s judgement affirms our right to sell the I-PEN and compete freely in the marketplace. The patent claims that TearLab sought to rely upon to shield their TearLab Osmolarity System from competition, have now been invalidated by the Court.”

Findings by the Court include:

I-MED Pharma Inc. is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists and the global eye care community. Established almost thirty years ago, I-MED Pharma creates and distributes innovative medical, surgical and veterinary eye care products worldwide. It continually researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degeneration, dry eye, glaucoma and Meibomian gland disease.

I-MED Pharma is proud to have been at the forefront of treating Dry Eye Syndrome as a serious disease and invests heavily into education and developing effective dry eye products.  I-MED Pharma’s ocular surface disease product range includes , , nutrition, and .

For further information, or for a copy of the full judgment, please contact I-MED Pharma at .  For further information on I-MED Pharma, please visit .

A photo accompanying this announcement is available at

More news and information about I-MED Pharma

Published By:

Globe Newswire: 20:55 GMT Tuesday 13th February 2018

Published: .

Search for other references to "pharma" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers